Mechanism of Action of Bempedoic Acid
Bempedoic acid lowers LDL cholesterol by inhibiting ATP-citrate lyase (ACL), an enzyme upstream of HMG-CoA reductase in the hepatic cholesterol synthesis pathway, which results in upregulation of LDL receptors and increased clearance of LDL from the blood. 1
Primary Mechanism: ACL Inhibition
Bempedoic acid functions as a prodrug that requires activation to exert its lipid-lowering effects 2:
- Liver-specific activation: The drug is converted to its active form (ETC-1002-CoA) by very-long-chain acyl-CoA synthetase-1 (ACSVL1), an enzyme expressed primarily in hepatocytes but not in skeletal muscle cells 1
- This tissue-selective activation explains why bempedoic acid avoids the muscle-related side effects commonly seen with statins 2, 3
The Cholesterol Synthesis Cascade
The mechanism works through the following pathway:
- ACL inhibition blocks the conversion of citrate to acetyl-CoA in the liver 1
- Reduced acetyl-CoA availability decreases downstream cholesterol biosynthesis 4
- Decreased intracellular cholesterol triggers compensatory upregulation of hepatic LDL receptors 2, 1
- Increased LDL receptor expression enhances clearance of circulating LDL particles, lowering blood LDL-C levels 2
Additional Mechanism: PPARα Activation
Recent research has identified a second mechanism of action that extends beyond cholesterol synthesis 5:
- Bempedoic acid directly binds to and activates peroxisome proliferator-activated receptor alpha (PPARα) 5
- This activation occurs independently of ACSVL1 conversion 5
- PPARα activation induces fatty acid oxidation pathways and contributes to the drug's lipid-lowering effects, particularly for triglycerides 5, 4
Clinical Implications of the Mechanism
Why It Works Synergistically with Statins
The positioning of ACL upstream of HMG-CoA reductase (the statin target) provides a mechanistic basis for synergistic LDL-C reduction 4:
- When combined with statins, bempedoic acid blocks cholesterol synthesis at an earlier step
- This dual inhibition produces greater LDL-C lowering (15-18% additional reduction) than increasing statin doses alone 2
- The combination achieves up to 38% LDL-C reduction when bempedoic acid is paired with ezetimibe 2
Muscle-Sparing Profile
The absence of ACSVL1 in skeletal muscle is the key mechanistic advantage 1, 3:
- Bempedoic acid cannot be activated in muscle tissue
- This provides a theoretical basis for reduced myotoxicity compared to statins
- Clinical trials confirmed approximately 24.5% LDL-C reduction in statin-intolerant patients 2
Metabolic Effects Beyond LDL-C
The dual mechanism (ACL inhibition + PPARα activation) produces broader metabolic benefits 5, 4:
- Triglyceride reduction through decreased fatty acid synthesis and enhanced fatty acid oxidation
- Anti-inflammatory effects via reduced hs-CRP and inflammatory cytokines 4, 6
- Improved endothelial function and reduced arterial stiffness, independent of LDL lowering 6
Important Mechanistic Caveats
Gallstone risk: ACL inhibition affects multiple pathways that can increase bile lithogenicity 7:
- Increased ABCG5/ABCG8 expression leads to greater cholesterol efflux into bile
- Inhibition of Cyp7a1 decreases bile acid synthesis
- Inhibition of OATP1B1/1B3 reduces bile acid reuptake
- These changes shift the bile composition toward cholesterol supersaturation
Minor metabolic effects: ACL inhibition also weakly inhibits OAT2 transporter, explaining the small increases in serum creatinine and uric acid observed in trials 1, though these elevations are generally not clinically significant 2.